Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.

IF 2.2 4区医学 Q3 HEMATOLOGY

Leukemia & Lymphoma Pub Date : 2024-07-25 DOI:10.1080/10428194.2024.2382923

Jacob Fang, Nakul Shankar, Liming Bao, Mary Haag, Billie Carstens, Changlee S Pang

{"title":"Near-tetraploidy/tetraploidy acute myeloid leukemia with clinical, pathologic and molecular characteristics.","authors":"Jacob Fang, Nakul Shankar, Liming Bao, Mary Haag, Billie Carstens, Changlee S Pang","doi":"10.1080/10428194.2024.2382923","DOIUrl":null,"url":null,"abstract":"Near-tetraploidy/tetraploidy (NT/T) is a cytogenetic alteration in acute myeloid leukemia (AML). In AML, specific chromosomal alterations are associated with clinical, morphological, and immunophenotypic features. The impact of cytogenetics on the prognosis of AML is well established. However, the prognostic implication of NT/T on AML remains unclear. Our aim is to further characterize the clinical, morphologic, immunophenotypic, molecular mutational, and prognostic features of NT/T AML. This retrospective chart review of NT/T AML cases showed NT/T AML was more common in older adult males, with predominately large blasts and myelodysplasia-related features. The most common lineage of dysplasia was dysgranulopoiesis in 77.8% of cases. Cases displayed multiple cytogenetic abnormalities, with only four showing NT/T as the sole abnormality. TP53 was the most common molecular mutation associated with NT/T AML (44.5%). Of the patients receiving treatment for NT/T AML, 80% achieved a CR. The median overall survival for the entire cohort was 4.5 months.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2382923","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Near-tetraploidy/tetraploidy (NT/T) is a cytogenetic alteration in acute myeloid leukemia (AML). In AML, specific chromosomal alterations are associated with clinical, morphological, and immunophenotypic features. The impact of cytogenetics on the prognosis of AML is well established. However, the prognostic implication of NT/T on AML remains unclear. Our aim is to further characterize the clinical, morphologic, immunophenotypic, molecular mutational, and prognostic features of NT/T AML. This retrospective chart review of NT/T AML cases showed NT/T AML was more common in older adult males, with predominately large blasts and myelodysplasia-related features. The most common lineage of dysplasia was dysgranulopoiesis in 77.8% of cases. Cases displayed multiple cytogenetic abnormalities, with only four showing NT/T as the sole abnormality. TP53 was the most common molecular mutation associated with NT/T AML (44.5%). Of the patients receiving treatment for NT/T AML, 80% achieved a CR. The median overall survival for the entire cohort was 4.5 months.

查看原文本刊更多论文

具有临床、病理和分子特征的近四倍体/四倍体急性髓性白血病。

近四倍体/四倍体（NT/T）是急性髓性白血病（AML）的一种细胞遗传学改变。在急性髓细胞白血病中，特定的染色体改变与临床、形态学和免疫表型特征相关。细胞遗传学对急性髓细胞白血病预后的影响已得到公认。然而，NT/T 对急性髓细胞白血病预后的影响仍不明确。我们的目的是进一步描述 NT/T AML 的临床、形态学、免疫表型、分子突变和预后特征。对NT/T型急性髓细胞白血病病例的回顾性病历回顾显示，NT/T型急性髓细胞白血病多见于老年男性，主要表现为大泡和骨髓增生异常相关特征。在77.8%的病例中，最常见的发育不良系是粒细胞生成障碍。病例显示多种细胞遗传学异常，只有4例显示NT/T为唯一异常。TP53 是与 NT/T AML 相关的最常见分子突变（44.5%）。在接受NT/T AML治疗的患者中，80%达到了CR。整个组群的中位总生存期为4.5个月。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia & Lymphoma 医学-血液学

CiteScore

4.10

自引率

3.80%

发文量

384

审稿时长

1.8 months

期刊介绍： Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor

文献相关原料

公司名称	产品信息	采购帮参考价格